Literature DB >> 21984977

Functional viability profiles of breast cancer.

Rachel Brough1, Jessica R Frankum, David Sims, Alan Mackay, Ana M Mendes-Pereira, Ilirjana Bajrami, Sara Costa-Cabral, Rumana Rafiq, Amar S Ahmad, Maria Antonietta Cerone, Rachael Natrajan, Rachel Sharpe, Kai-Keen Shiu, Daniel Wetterskog, Konstantine J Dedes, Maryou B Lambros, Teeara Rawjee, Spiros Linardopoulos, Jorge S Reis-Filho, Nicholas C Turner, Christopher J Lord, Alan Ashworth.   

Abstract

UNLABELLED: The design of targeted therapeutic strategies for cancer has largely been driven by the identification of tumor-specific genetic changes. However, the large number of genetic alterations present in tumor cells means that it is difficult to discriminate between genes that are critical for maintaining the disease state and those that are merely coincidental. Even when critical genes can be identified, directly targeting these is often challenging, meaning that alternative strategies such as exploiting synthetic lethality may be beneficial. To address these issues, we have carried out a functional genetic screen in >30 commonly used models of breast cancer to identify genes critical to the growth of specific breast cancer subtypes. In particular, we describe potential new therapeutic targets for PTEN-mutated cancers and for estrogen receptor-positive breast cancers. We also show that large-scale functional profiling allows the classification of breast cancers into subgroups distinct from established subtypes. SIGNIFICANCE: Despite the wealth of molecular profiling data that describe breast tumors and breast tumor cell models, our understanding of the fundamental genetic dependencies in this disease is relatively poor. Using high-throughput RNA interference screening of a series of pharmacologically tractable genes, we have generated comprehensive functional viability profiles for a wide panel of commonly used breast tumor cell models. Analysis of these profiles identifies a series of novel genetic dependencies, including that of PTEN-null breast tumor cells upon mitotic checkpoint kinases, and provides a framework upon which additional dependencies and candidate therapeutic targets may be identified.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21984977      PMCID: PMC3188379          DOI: 10.1158/2159-8290.CD-11-0107

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  42 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

2.  More powerful procedures for multiple significance testing.

Authors:  Y Hochberg; Y Benjamini
Journal:  Stat Med       Date:  1990-07       Impact factor: 2.373

3.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Authors:  T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

Review 4.  A census of amplified and overexpressed human cancer genes.

Authors:  Thomas Santarius; Janet Shipley; Daniel Brewer; Michael R Stratton; Colin S Cooper
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

5.  Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.

Authors:  Huan Pang; Rory Flinn; Antonia Patsialou; Jeffrey Wyckoff; Evanthia T Roussos; Haiyan Wu; Maria Pozzuto; Sumanta Goswami; John S Condeelis; Anne R Bresnick; Jeffrey E Segall; Jonathan M Backer
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

6.  A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor.

Authors:  Nicholas C Turner; Christopher J Lord; Elizabeth Iorns; Rachel Brough; Sally Swift; Richard Elliott; Sydonia Rayter; Andrew N Tutt; Alan Ashworth
Journal:  EMBO J       Date:  2008-04-03       Impact factor: 11.598

Review 7.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

Authors:  José Baselga; Sandra M Swain
Journal:  Nat Rev Cancer       Date:  2009-06-18       Impact factor: 60.716

8.  53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.

Authors:  Peter Bouwman; Amal Aly; Jose M Escandell; Mark Pieterse; Jirina Bartkova; Hanneke van der Gulden; Sanne Hiddingh; Maria Thanasoula; Atul Kulkarni; Qifeng Yang; Bruce G Haffty; Johanna Tommiska; Carl Blomqvist; Ronny Drapkin; David J Adams; Heli Nevanlinna; Jiri Bartek; Madalena Tarsounas; Shridar Ganesan; Jos Jonkers
Journal:  Nat Struct Mol Biol       Date:  2010-05-09       Impact factor: 15.369

9.  Cancer proliferation gene discovery through functional genomics.

Authors:  Michael R Schlabach; Ji Luo; Nicole L Solimini; Guang Hu; Qikai Xu; Mamie Z Li; Zhenming Zhao; Agata Smogorzewska; Mathew E Sowa; Xiaolu L Ang; Thomas F Westbrook; Anthony C Liang; Kenneth Chang; Jennifer A Hackett; J Wade Harper; Gregory J Hannon; Stephen J Elledge
Journal:  Science       Date:  2008-02-01       Impact factor: 47.728

10.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

Authors:  Ana M Mendes-Pereira; Sarah A Martin; Rachel Brough; Afshan McCarthy; Jessica R Taylor; Jung-Sik Kim; Todd Waldman; Christopher J Lord; Alan Ashworth
Journal:  EMBO Mol Med       Date:  2009-09       Impact factor: 12.137

View more
  71 in total

1.  The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor.

Authors:  Kristen L Karlin; Gourish Mondal; Jessica K Hartman; Siddhartha Tyagi; Sarah J Kurley; Chris S Bland; Tiffany Y T Hsu; Alexander Renwick; Justin E Fang; Ilenia Migliaccio; Celetta Callaway; Amritha Nair; Rocio Dominguez-Vidana; Don X Nguyen; C Kent Osborne; Rachel Schiff; Li-Yuan Yu-Lee; Sung Y Jung; Dean P Edwards; Susan G Hilsenbeck; Jeffrey M Rosen; Xiang H-F Zhang; Chad A Shaw; Fergus J Couch; Thomas F Westbrook
Journal:  Cell Rep       Date:  2014-11-06       Impact factor: 9.423

2.  Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping.

Authors:  Christina Laufer; Bernd Fischer; Maximilian Billmann; Wolfgang Huber; Michael Boutros
Journal:  Nat Methods       Date:  2013-04-07       Impact factor: 28.547

3.  Cerebellar Ataxia and Coenzyme Q Deficiency through Loss of Unorthodox Kinase Activity.

Authors:  Jonathan A Stefely; Floriana Licitra; Leila Laredj; Andrew G Reidenbach; Zachary A Kemmerer; Anais Grangeray; Tiphaine Jaeg-Ehret; Catherine E Minogue; Arne Ulbrich; Paul D Hutchins; Emily M Wilkerson; Zheng Ruan; Deniz Aydin; Alexander S Hebert; Xiao Guo; Elyse C Freiberger; Laurence Reutenauer; Adam Jochem; Maya Chergova; Isabel E Johnson; Danielle C Lohman; Matthew J P Rush; Nicholas W Kwiecien; Pankaj K Singh; Anna I Schlagowski; Brendan J Floyd; Ulrika Forsman; Pavel J Sindelar; Michael S Westphall; Fabien Pierrel; Joffrey Zoll; Matteo Dal Peraro; Natarajan Kannan; Craig A Bingman; Joshua J Coon; Philippe Isope; Hélène Puccio; David J Pagliarini
Journal:  Mol Cell       Date:  2016-08-04       Impact factor: 17.970

Review 4.  Use of RNAi screens to uncover resistance mechanisms in cancer cells and identify synthetic lethal interactions.

Authors:  Paul Diehl; Donato Tedesco; Alex Chenchik
Journal:  Drug Discov Today Technol       Date:  2014-03

Review 5.  From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets.

Authors:  Cheryl Eifert; R Scott Powers
Journal:  Nat Rev Cancer       Date:  2012-08       Impact factor: 60.716

6.  Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.

Authors:  Lauren S Fink; Alexander Beatty; Karthik Devarajan; Suraj Peri; Jeffrey R Peterson
Journal:  Mol Cancer Ther       Date:  2014-10-24       Impact factor: 6.261

7.  Polo-like kinase 4 inhibition: a strategy for cancer therapy?

Authors:  Andrew J Holland; Don W Cleveland
Journal:  Cancer Cell       Date:  2014-08-11       Impact factor: 31.743

8.  Mitochondrial ADCK3 employs an atypical protein kinase-like fold to enable coenzyme Q biosynthesis.

Authors:  Jonathan A Stefely; Andrew G Reidenbach; Arne Ulbrich; Krishnadev Oruganty; Brendan J Floyd; Adam Jochem; Jaclyn M Saunders; Isabel E Johnson; Catherine E Minogue; Russell L Wrobel; Grant E Barber; David Lee; Sheng Li; Natarajan Kannan; Joshua J Coon; Craig A Bingman; David J Pagliarini
Journal:  Mol Cell       Date:  2014-12-11       Impact factor: 17.970

Review 9.  Targeting the cell cycle in breast cancer: towards the next phase.

Authors:  K L Thu; I Soria-Bretones; T W Mak; D W Cescon
Journal:  Cell Cycle       Date:  2018-09-11       Impact factor: 4.534

10.  Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.

Authors:  Kevin P Williams; Jennifer L Allensworth; Shalonda M Ingram; Ginger R Smith; Amy J Aldrich; Jonathan Z Sexton; Gayathri R Devi
Journal:  Cancer Lett       Date:  2013-05-17       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.